Eli Lilly blows past quarterly estimates, posts strong outlook as Zepbound and Mounjaro sales soar
Eli Lilly’s full-year guidance comes in stark contrast to the outlook of Novo Nordisk, which warned it sees sales and profit declining as much as 13% this year.
原文: https://www.cnbc.com/2026/02/04/eli-lilly-lly-earnings-q4-2025.html
Last Update:
4 2 月, 2026